Brazilian regulator Anvisa had in March denied a certificate for good manufacturing practices to Bharat Biotech citing certain violations of GMP at Bharat Biotech facility. Anvisa’s clearance is a necessary step for the country’s process of authorising this vaccine for emergency use.Bharat Biotech submits fresh request before Brazilian regulator for Covaxin GMP certificate
Brazilian regulator Anvisa had in March denied a certificate for good manufacturing practices to Bharat Biotech citing certain violations of GMP at Bharat Biotech facility. Anvisa’s clearance is a necessary step for the country’s process of authorising this vaccine for emergency use.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment